Risedronate Sodium

CAS No. 115436-72-1

Risedronate Sodium( —— )

Catalog No. M10542 CAS No. 115436-72-1

Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG 39 In Stock
100MG 65 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Risedronate Sodium
  • Note
    Research use only, not for human use.
  • Brief Description
    Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
  • Description
    Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HAP| FPS
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    115436-72-1
  • Formula Weight
    305.09
  • Molecular Formula
    C7H10NNaO7P2
  • Purity
    >98% (HPLC)
  • Solubility
    Water: 2 mg/mL (6.55 mM)
  • SMILES
    O.O.O.O.O.[Na+].OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O.OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)([O-])=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Bergstrom JD, et al. Arch Biochem Biophys. 2000 Jan 1;373(1):231-4
molnova catalog
related products
  • Besifovir

    Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM).

  • JNJ-632

    JNJ-632 (JNJ632) is a novel potent HVV capsid assembly modulator and HBV replication inhibitor.

  • IR415

    IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression.